Skip to main content
. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625

Figure 4.

Figure 4

Distant metastasis-free survival (DMFS) of eligible patients (pts) participating in the CASVAC-0401 study (*p = 0.022, Gehan–Breslow–Wilcoxon test) (A). Quality of life (QOL) in all eligible pts participating in CASVAC-0401, evaluated by the European Organization for Research and Treatment of Cancer—Quality of Life Questionnaire (“EORTC QLQ-C30, v 3.0”). Mean and SD are shown (score 1 ***p < 0.0001; score 2 ***p < 0.0001). Score 1 = a higher value implies a poorer QOL; score 2 = a lower value implies a poorer QOL (B).